United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 95.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,378 shares of the biotechnology company's stock after selling 75,464 shares during the period. Nordea Investment Management AB's holdings in United Therapeutics were worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of UTHR. Meiji Yasuda Asset Management Co Ltd. boosted its stake in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after purchasing an additional 33 shares in the last quarter. Toronto Dominion Bank lifted its holdings in United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after buying an additional 37 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after acquiring an additional 42 shares during the last quarter. First Citizens Bank & Trust Co. grew its holdings in United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after acquiring an additional 48 shares during the period. Finally, Signaturefd LLC grew its stake in United Therapeutics by 8.8% during the third quarter. Signaturefd LLC now owns 633 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 51 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent research reports. Oppenheimer increased their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. UBS Group lifted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Wednesday, January 8th. The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research report on Friday, November 1st. Finally, HC Wainwright increased their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $378.36.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $361.80 on Monday. The firm has a market capitalization of $16.15 billion, a PE ratio of 15.89, a PEG ratio of 1.05 and a beta of 0.57. The stock's fifty day moving average is $370.50 and its 200 day moving average is $352.66. United Therapeutics Co. has a fifty-two week low of $208.62 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.38 EPS. Equities analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $350.00, for a total transaction of $2,730,000.00. Following the completion of the sale, the chief financial officer now owns 6,978 shares of the company's stock, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 14,700 shares of the firm's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $374.46, for a total value of $5,504,562.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $964,983.42. The trade was a 85.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 134,630 shares of company stock worth $50,725,716 in the last ninety days. 11.90% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.